# Microt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microt

- Headquarters: Seoul, South Korea
- Website: www.microtinc.com/
- Total disclosed funding: $6.7M
- Latest round: Series A (Jun 1, 2021)
- Investors on record: 5

## About

Based in South Korea, Microt Inc. focuses on developing medical products that address ocular health challenges, particularly glaucoma, alongside skincare solutions for the delicate area around the eyes.Founded in 2019 and headquartered in Seoul, South Korea, Microt Inc. specializes in medical products targeting ocular health. The company is led by CEO Jong-cheol Han. Microt has successfully raised a total of KRW 11 billion, primarily during its most recent Series B funding round that occurred on July 31, 2025, from various investors including COMES Investment and Horizon Investment. With two deals recorded, Microt has shown a commitment to addressing specific health challenges in its sector.Microt Inc. specializes in developing medical products aimed at addressing specific ocular health issues, particularly focused on glaucoma and related eye conditions. Their core offerings include advanced therapeutic solutions designed to mitigate optic nerve damage caused by elevated intraocular pressure, commonly associated with glaucoma. The company also provides skincare products formulated to alleviate dryness and damage around the sensitive skin surrounding the eyes. These products are primarily targeted toward healthcare professionals, including ophthalmologists and dermatologists, who prescribe them to patients experiencing symptoms related to glaucoma and dry skin conditions. Microt's products are marketed and sold in both domestic and international markets, with a particular focus on regions with a high prevalence of ocular diseases, ensuring accessibility to a broad user base that includes both healthcare providers and end consumers.Microt Inc. generates revenue through direct sales of its medical and skincare products to healthcare providers and institutions, employing a B2B model that facilitates transactions with clinics and hospitals. The pricing structure reflects the value of their specialized offerings, with various products tailored to different treatment needs and skin conditions. Partnerships with healthcare facilities and practitioners enhance market penetration, allowing for a consistent flow of prescriptions and product recommendations. The company’s flagship products, aimed at treating glaucoma and promoting eye area skincare, contribute significantly to its revenue streams through established relationships with medical professionals who serve a diverse patient demographic seeking effective solutions for their ocular health concerns.In July 2025, Microt Inc. raised KRW 11 billion in Series B funding from new investors Korea Investment Partners and Seoul Investment Partners, as well as returning investors East Gate Partners. With these resources, Microt plans to develop upcoming products aimed at enhancing ocular treatments and skincare solutions. Additionally, the company is strategizing to expand into new geographical markets, with specific focus on regions showing high demand for ocular health products, leveraging the fresh capital to support this expansion.

## Funding rounds

- Series A, Jun 1, 2021, $6.7M — IMM Investment, Kiwoom Investment, Enlight Ventures, Tigris Investment, Unlimited Partners

## Investors

- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series A
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series A
- Unlimited Partners — Series A